behaviors (20%). Other modes of transmission (occupational, hemodialysis, household and perinatal) accounted for approximately 10% of infection. 8 A potential risk factor can be identified in approximately 90% of persons infected with HCV. In the remaining 10%, no recognized source of infection can be identified, although most persons in this category associated with low socio-economic level. 9 Risk for sexual transmission is rare and occurs in <5% of those couples where one of the individual is infected with HCV. Mother to infant transmission of HCV is possible but uncommon, and occurred in 3-5% of babies born to HCV positive mothers. 10 HCV is endemic in most parts of the world, with an estimated overall prevalence of 3%, representing approximately 170 million HCV-infected persons world-wide. 11 The estimated figures are 0.3% in New Zealand and 4% in Combodia. 12 However, there is considerable geographic variation in the incidence and prevalence of HCV infection.Much of the variability between regions can be explained by the frequency and extent to which different risk factors like injection drug use accounting for 60 to 80% 13 , transfusions and transplants 5 to 13% 13 , unsafe injections and other healthcare related procedures 2 to 18%, occupational exposures 0 to 7% 14 , perinatal transmission 0 to 40% 15 have been contributed to the transmission of HCV. â-thalassemia major patients are among the high risk groups for HCV infection due to repeated blood transfusion. In contrast to the low rate of HCV infection in healthy population, thalassemic patients reveal high prevalence of HCV infection because of repeated exposure to blood. Infections among these patients ranged from 11.1% to 63% in various studies [16] [17] [18] and rate of infection in these patients correlate with the amount of blood transfused. Studies from Italy, Iran and Thailand showed a high prevalence of anti HCV antibody of 60%, 27.1% and 20.2% respectively. 19, [20] [21] [22] Seroprevalence of anti-HCV among thalassemic patients was 56.8% in Pakistan. 23 A study from Bangladesh revealed that anti-HCV seropositivity was 12.5% in thalassemic children compared to 0.9% among age and sex matched control group. 24 This study was conducted with the aim to find out anti-HCV sero-prevalence among thalassemic patients.
Materials and Methods:
This cross sectional study was carried out during the period of April 2007 to April 2008 among thalassemic patients with history of multiple blood transfusion (>20 units). Total 200 thalassemic patients were enrolled from Thalassemia Samity Hospital, Green Road, Bangladesh Thalassemia Foundation, Dhanmondi, and from Department of Transfusion Medicine, BSMMU, Dhaka. After taking informed written consent of the subjects all necessary information were recorded in a pre-designed structured questionnaire. After that 3.0ml of venous blood was collected in a sterile test tube aseptically by venipuncture with sterile disposable syringe. Blood was tested for anti HCV by commercial kit according to standard operating procedure of manufacturer's instruction (Anti HCV test done by Excel HCV rapid device, made in USA). 25 Sensitivity of this method was found to be 99% with Specificity of 98.6%. 25, 26 All positive cases were confirmed by ELISA method. Statistical analysis was performed using SPSS program. Odds ratio and chi-square test were done to test the significance of the factors of study in relation with the seroprevalence of anti-HCV antibodies. Logistic regression analysis was applied to identify the risk factors. p<0.05 was considered significant.
Results:
Out of 200 patients 33 (16.5%) were anti HCV positive and 167 (83.5%) were anti HCV negative (Fig-1) 
Fig-1: Distribution of patients according to anti HCV status.
Among HCV positive individuals 21 (63.6%) were male and 12 (36.4%) were female and among HCV negative individuals 100 (66%) were male and 57 (34%) were female ( Table-1) . There is male predominance with a male to female ratio 1.7:1. Table-IV) . On clinical examination, out of 200 patients all (100%) had jaundice and hepatomegaly, 198 (99%) patients had splenomegaly, 15 (7.5%) had oedema, 7 (3.5%) had clubbing. Spider nevi, palmar erythema, gynaecomastia, testicular atrophy, engorged abdominal vein, and ascities were not found in any individual.
Discussion:
Hepatitis C virus infection is a major cause of liver related morbidity and mortality and represents a major public health problem world wide. HCV infection is more notorious than hepatitis B virus infection (HBV) because of greater risk of chronicity and other sequelae of liver disease like chronic hepatitis, cirrhosis of liver and heaptocellular carcinoma. Its prevalence is lower than hepatitis B virus. The overall prevalence of HCV infection is 1% to 2% in most countries but the distribution of HCV varies considerably among different populations. 8 HCV is most frequently transmitted by percutaneous exposure to infected blood or blood derived body fluids and very high rates of HCV infection are found among persons exposed to HCV through these routes. HCV prevalence rate in USA is about 1.8% 13 
Conclusion:
From this study it was evident that, majority (68.5%) of patients were below 20 years of age and there is male preponderance with a male to female ratio 1.7:1. Out of 200 thalassemic patients 16.5% were found anti HCV positive. Anti HCV positivity increased with duration of exposure and number of blood transfusion. It was found that 22.9% of patients who had duration of exposure for more than 10 years and 36.4% who had history of blood transfusion for more than 40 units were positive for anti HCV. It is difficult to comment on risk factors in this small population. To get dependable conclusion regarding prevalence of HCV, further extensive studies with larger sample size should be carried out.
